Integra LifeSciences (NASDAQ:IART) Stock Rating Cut to “Strong Sell” at Zacks Research

Posted by George Bondi on Oct 28th, 2026

Zacks Research downgraded shares of Integra LifeSciences (NASDAQ:IART – Free Report) from a hold rating to a strong sell rating in a research report report published on Monday,Zacks reports.

A number of other research firms also recently weighed in on IART. BMO Capital Markets restated a “market perform” rating and issued a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a research report on Thursday, October 22nd. UBS Group set a $14.00 price target on Integra LifeSciences and gave the company a “neutral” rating in a research note on Tuesday. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. JPMorgan Chase & Co. lowered their price target on Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a research report on Thursday, October 22nd. Finally, Wells Fargo & Company set a $13.00 price objective on Integra LifeSciences and gave the stock an “equal weight” rating in a research note on Thursday, October 22nd. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $16.12.

Read Our Latest Research Report on IART

Integra LifeSciences Trading Down 0.9%

Integra LifeSciences stock opened at $11.99 on Monday. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The stock has a market cap of $932.50 million, a price-to-earnings ratio of 70.53 and a beta of 1.21. The company’s 50-day moving average price is $15.11 and its two-hundred day moving average price is $14.10.

Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same period in the prior year, the company posted ($0.07) earnings per share. Research analysts expect that Integra LifeSciences will post 2.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY acquired a new position in shares of Integra LifeSciences in the second quarter worth about $61,766,000. Hsbc Holdings PLC purchased a new position in shares of Integra LifeSciences in the fourth quarter worth approximately $879,000. Bank of New York Mellon Corp purchased a new position in shares of Integra LifeSciences in the second quarter worth approximately $8,723,000. Maverick Capital Ltd. acquired a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $679,000. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $280,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.